KORU Medical Systems (NASDAQ:KRMD) CTO Eric Schiller Acquires 5,000 Shares

KORU Medical Systems, Inc. (NASDAQ:KRMD) CTO Eric Schiller purchased 5,000 shares of the company’s stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $3.91 per share, with a total value of $19,550.00. Following the completion of the purchase, the chief technology officer directly owned 5,000 shares of the company’s stock, valued at $19,550. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

KORU Medical Systems Trading Up 1.0%

NASDAQ:KRMD traded up $0.04 on Wednesday, hitting $4.00. 111,917 shares of the stock were exchanged, compared to its average volume of 172,817. The stock has a market cap of $183.73 million, a PE ratio of -80.00 and a beta of 0.43. The stock has a fifty day moving average of $4.21 and a 200-day moving average of $4.84. KORU Medical Systems, Inc. has a fifty-two week low of $2.63 and a fifty-two week high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $11.76 million during the quarter, compared to analyst estimates of $11.28 million. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%. As a group, analysts predict that KORU Medical Systems, Inc. will post -0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. B. Riley Financial upped their target price on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Wall Street Zen downgraded KORU Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, KORU Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Institutional Investors Weigh In On KORU Medical Systems

Several institutional investors and hedge funds have recently modified their holdings of KRMD. Simcoe Capital LLC purchased a new stake in shares of KORU Medical Systems in the fourth quarter worth about $3,921,000. Geode Capital Management LLC boosted its position in shares of KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock worth $3,571,000 after buying an additional 501,875 shares during the period. Acuitas Investments LLC boosted its position in shares of KORU Medical Systems by 89.6% in the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock worth $2,923,000 after buying an additional 360,594 shares during the period. First Light Asset Management LLC boosted its holdings in KORU Medical Systems by 5.1% in the second quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after purchasing an additional 226,700 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in KORU Medical Systems by 189.5% in the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after purchasing an additional 158,914 shares during the last quarter. Hedge funds and other institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.